ArticleFolia microbiologica2026
Co-existence of blaCTX-M and mcr-1 in avian pathogenic Escherichia coli in Southern Xinjiang: current status and antimicrobial resistance characteristics.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Extended-spectrum β-lactamases (ESBLs) constitute one of the principal mechanisms underlying multidrug resistance (MDR) in avian pathogenic Escherichia coli (APEC). The coexistence of ESBL-encoding genes, particularly blaCTX-M, together with the plasmid-mediated colistin resistance gene mcr-1 in APEC raises serious concern, as it undermines the effectiveness of third-generation cephalosporins and colistin. To clarify the current epidemiological status and potential transmission risks associated with the co-occurrence of ESBL and mcr-1 genes in southern Xinjiang, 133 liver samples from chickens that had died after exhibiting clinical signs consistent with colibacillosis were collected, from which 100 of these isolates (75.2%, 100/133) were confirmed as APEC. The double-disk diffusion test revealed that 65 strains (65.0%, 65/100) were ESBL-producing. Among these ESBL-producing APEC isolates, resistance rates to ampicillin, cefazolin, ceftiofur, and cefoxitin were 100% (65/65), 100% (65/65), 92.3% (60/65), and 4.6% (3/65, intermediate/susceptible), respectively. PCR detection revealed that 95.4% (62/65) carried blaCTX-M and 93.8% (61/65) carried blaTEM and five isolates (7.7%, 5/65) were resistant to colistin and carried the mcr-1 gene. Integron analysis revealed that int1 was detected in 98.5% (64/65) of the ESBL-APEC isolates. Notably, all five mcr-1-positive strains co-harbored int1. These five isolates exhibited MDR phenotypes and were assigned to phylogenetic groups A (n = 1), B1 (n = 3), and D (n = 1). Whole-genome sequencing (WGS) revealed that the five mcr-1-positive APEC strains belonged to four sequence types (STs): ST6792 (n = 1), ST1196 (n = 2), ST155 (n = 1), and ST162 (n = 1), and harbored three blaCTX-M subtypes (blaCTX-M-55 [n = 3], blaCTX-M-64 [n = 1], and blaCTX-M-65[n = 1]). Furthermore, these strains carried IncI2 or IncFIB plasmid replicons alongside the int1 integrase gene, highlighting the co-occurrence of critical resistance determinants with mobile genetic elements known to facilitate horizontal dissemination. The coexistence of blaCTX-M and mcr-1 in high-risk clones such as ST155 and ST162, which are associated with human infections worldwide, indicates that the region faces a threat from multidrug-resistant strains and a potential risk of cross-species transmission. Given the limited geographic scope and sample size, our findings should be considered a preliminary warning. Future studies with expanded sampling and experimental validation of horizontal transfer are needed to fully assess the transmission risks.
Indexed as
Identifiers
42090104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.